News

Article

EMPOWERing the Next Generation

Author(s):

Erica Koenig, PhD

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

CONFERENCE REPORTER

Erica Koenig, PhD, gives an overview of Cerevel Therapeutics and discusses EMPOWER, a phase 2 clinical trial evaluating emraclidine for the treatment of schizophrenia. Koenig presented this research in a poster presentation at Psych Congress 2023.

Dr Koenig is program lead of emraclidine and senior director of global clinical development at Cerevel Therapeutics.

Related Videos
schizophrenia
sc
schizophrenia
clozapine
brain
cognition
clock
clozapine
steering wheel
schizophrenia
Related Content
pills
April 30th 2025

April in Review: Updates on the Psychiatric Treatment Pipeline

Leah Kuntz
Treating ‘Morally Objectionable’ Patients
September 27th 2021

Treating ‘Morally Objectionable’ Patients

James L. Knoll IV, MD
pharmacist
April 16th 2025

Treating Schizophrenia: Bringing Together Pharmacists and Clinicians for Patient Care

Michael McGuire, PharmD
More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle
May 11th 2021

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

Anita H. Clayton, MD
pregnant
April 11th 2025

Examining a Case of Acute Late-Pregnancy Psychosis: How Best to Coordinate Care

Cecilia A. Westbrook, MD, PhD Meredith Spada, MD Elizabeth M. Hovis, MD Jacob Larkin, MD Alexandra Nicholas, MD Luke Swider, MD Jonathan Yadlosky, MD Joseph S. DeRenzo, MD Adam P. Dunmore, MD Jennifer L. Kloesz, MD, FAAP Linda Dudas, RNC, MSN, CNL John Silipigni, MSW, MBA Priya Gopalan, MD
bipolar disorder
April 7th 2025

Online Survey Reveals Clinicians’ Top Concerns in BDI, Schizophrenia Treatment

Grace Koennecke
© 2025 MJH Life Sciences

All rights reserved.